United States Veterinary Oncology Diagnostics Market By Animal Type (Canine, Feline, Others), By Test Type (Blood Tests, Biopsy, Genome Testing, Endoscopy, Urinalysis, Imaging), By Cancer Type (Lymphoma, Sarcomas, Mammary Gland Tumors, Skin Cancers, Others), By End User (Reference Laboratories, Veterinary Hospitals and Clinics, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F
Market Overview
The United States Veterinary Oncology Diagnostics Market, valued at USD 985.24 million in 2024, is projected to reach USD 1,607.87 million by 2030, growing at a CAGR of 8.48%. This growth is driven by increasing awareness among pet owners about early cancer detection and the importance of proactive health screenings, especially for older animals or those predisposed to cancer. With rising demand, advanced technologies like molecular diagnostics, imaging, and biomarker testing are increasingly being adopted to facilitate early and accurate diagnoses. Moreover, personalized cancer treatments and minimally invasive diagnostic procedures are gaining traction, supported by emerging AI-based diagnostic systems that promise faster, more precise results and enhance treatment outcomes.
Key Market Drivers
Rising Prevalence of Cancer in Pets
The increasing incidence of cancer among pets is a primary driver of the United States Veterinary Oncology Diagnostics Market. Data shows that 1 in 4 dogs develop neoplasia during their lifetime, with almost half of dogs over ten diagnosed with cancer. In 2023 alone, approximately 4.2 million dogs in the U.S. were diagnosed, equating to about 53 cases per 1,000 dogs annually. This significant prevalence has amplified the demand for precise and early diagnostic tools. Veterinarians now rely on advanced technologies—such as molecular diagnostics, imaging tools, and blood tests—to detect cancer in its earliest stages, often before clinical symptoms arise. This enables timely interventions, improving treatment success. The growing awareness has also led to routine cancer screenings becoming a norm in veterinary visits. Specialized oncology clinics and state-of-the-art diagnostic services further bolster the market’s expansion. As both pet owners and veterinary professionals increasingly prioritize cancer detection, the demand for oncology diagnostics is expected to remain strong throughout the forecast period.
Key Market Challenges
Limited Access to Specialized Veterinary Oncologists
One of the main hurdles in the United States Veterinary Oncology Diagnostics Market is the limited availability of specialized veterinary oncologists. While metropolitan areas often have access to such professionals, rural regions face a critical shortage, resulting in delayed diagnosis and treatment. The inconvenience and cost of traveling to distant clinics discourage many pet owners from seeking specialized care, leading to missed opportunities for early intervention. The small number of trained oncologists has created bottlenecks, particularly as awareness of pet cancer rises and more diagnostics are sought. This shortage also impacts the adoption of advanced technologies, as clinics lacking oncology specialists may deprioritize investment in cutting-edge tools. Until broader access to specialized professionals is achieved, the market may face constraints that hinder treatment efficacy and the expansion of diagnostic capabilities.
Key Market Trends
Shift Toward Non-Invasive Diagnostics
There is a growing preference in the United States Veterinary Oncology Diagnostics Market for non-invasive diagnostic methods due to their reduced physical burden and improved comfort for pets. Traditional methods like biopsies are being replaced or supplemented by options such as blood tests, liquid biopsies, MRIs, and ultrasounds, which provide accurate results with minimal discomfort. Liquid biopsies, for instance, can detect cancer-related biomarkers in blood, facilitating early detection without surgery. This trend is supported by advancements in high-resolution imaging and molecular diagnostics, which improve accuracy and speed. Pet owners and veterinarians increasingly favor these methods for their convenience, safety, and potential to monitor disease progression with ease, contributing to their growing adoption and market expansion.
Key Market Players
In this report, the United States Veterinary Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the United States Veterinary Oncology Diagnostics Market.
Available Customizations:
United States Veterinary Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The United States Veterinary Oncology Diagnostics Market, valued at USD 985.24 million in 2024, is projected to reach USD 1,607.87 million by 2030, growing at a CAGR of 8.48%. This growth is driven by increasing awareness among pet owners about early cancer detection and the importance of proactive health screenings, especially for older animals or those predisposed to cancer. With rising demand, advanced technologies like molecular diagnostics, imaging, and biomarker testing are increasingly being adopted to facilitate early and accurate diagnoses. Moreover, personalized cancer treatments and minimally invasive diagnostic procedures are gaining traction, supported by emerging AI-based diagnostic systems that promise faster, more precise results and enhance treatment outcomes.
Key Market Drivers
Rising Prevalence of Cancer in Pets
The increasing incidence of cancer among pets is a primary driver of the United States Veterinary Oncology Diagnostics Market. Data shows that 1 in 4 dogs develop neoplasia during their lifetime, with almost half of dogs over ten diagnosed with cancer. In 2023 alone, approximately 4.2 million dogs in the U.S. were diagnosed, equating to about 53 cases per 1,000 dogs annually. This significant prevalence has amplified the demand for precise and early diagnostic tools. Veterinarians now rely on advanced technologies—such as molecular diagnostics, imaging tools, and blood tests—to detect cancer in its earliest stages, often before clinical symptoms arise. This enables timely interventions, improving treatment success. The growing awareness has also led to routine cancer screenings becoming a norm in veterinary visits. Specialized oncology clinics and state-of-the-art diagnostic services further bolster the market’s expansion. As both pet owners and veterinary professionals increasingly prioritize cancer detection, the demand for oncology diagnostics is expected to remain strong throughout the forecast period.
Key Market Challenges
Limited Access to Specialized Veterinary Oncologists
One of the main hurdles in the United States Veterinary Oncology Diagnostics Market is the limited availability of specialized veterinary oncologists. While metropolitan areas often have access to such professionals, rural regions face a critical shortage, resulting in delayed diagnosis and treatment. The inconvenience and cost of traveling to distant clinics discourage many pet owners from seeking specialized care, leading to missed opportunities for early intervention. The small number of trained oncologists has created bottlenecks, particularly as awareness of pet cancer rises and more diagnostics are sought. This shortage also impacts the adoption of advanced technologies, as clinics lacking oncology specialists may deprioritize investment in cutting-edge tools. Until broader access to specialized professionals is achieved, the market may face constraints that hinder treatment efficacy and the expansion of diagnostic capabilities.
Key Market Trends
Shift Toward Non-Invasive Diagnostics
There is a growing preference in the United States Veterinary Oncology Diagnostics Market for non-invasive diagnostic methods due to their reduced physical burden and improved comfort for pets. Traditional methods like biopsies are being replaced or supplemented by options such as blood tests, liquid biopsies, MRIs, and ultrasounds, which provide accurate results with minimal discomfort. Liquid biopsies, for instance, can detect cancer-related biomarkers in blood, facilitating early detection without surgery. This trend is supported by advancements in high-resolution imaging and molecular diagnostics, which improve accuracy and speed. Pet owners and veterinarians increasingly favor these methods for their convenience, safety, and potential to monitor disease progression with ease, contributing to their growing adoption and market expansion.
Key Market Players
- Zoetis Inc.
- Neogen Corporation
- Antech Diagnostics, Inc.
- IDEXX Laboratories, Inc.
- Embark Veterinary, Inc.
- Boehringer Ingelheim Animal Health USA Inc.
- Arizona Veterinary Oncology
- Varian Medical Systems, Inc.
- Merck & Co., Inc.
- Oncotect, Inc.
In this report, the United States Veterinary Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- United States Veterinary Oncology Diagnostics Market, By Animal Type:
- Canine
- Feline
- Others
- United States Veterinary Oncology Diagnostics Market, By Test Type:
- Blood Tests
- Biopsy
- Genome testing
- Endoscopy
- Urinalysis
- Imaging
- United States Veterinary Oncology Diagnostics Market, By Cancer Type:
- Lymphoma
- Sarcomas
- Mammary Gland Tumors
- Skin Cancers
- Others
- United States Veterinary Oncology Diagnostics Market, By End User:
- Reference Laboratories
- Veterinary Hospitals and Clinics
- Others
- United States Veterinary Oncology Diagnostics Market, By Region:
- North-East
- Mid-West
- West
- South
Company Profiles: Detailed analysis of the major companies present in the United States Veterinary Oncology Diagnostics Market.
Available Customizations:
United States Veterinary Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Animal Type (Canine, Feline, Others)
5.2.2. By Test Type (Blood Tests, Biopsy, Genome Testing, Endoscopy, Urinalysis, Imaging)
5.2.3. By Cancer Type (Lymphoma, Sarcomas, Mammary Gland Tumors, Skin Cancers, Others)
5.2.4. By End User (Reference Laboratories, Veterinary Hospitals and Clinics, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH-EAST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Animal Type
6.2.2. By Test Type
6.2.3. By Cancer Type
6.2.4. By End User
7. MID-WEST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Animal Type
7.2.2. By Test Type
7.2.3. By Cancer Type
7.2.4. By End User
8. WEST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Animal Type
8.2.2. By Test Type
8.2.3. By Cancer Type
8.2.4. By End User
9. SOUTH VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Animal Type
9.2.2. By Test Type
9.2.3. By Cancer Type
9.2.4. By End User
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. POLICY & REGULATORY LANDSCAPE
13. UNITED STATES ECONOMIC PROFILE
14. UNITED STATES VETERINARY ONCOLOGY DIAGNOSTICS MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. COMPETITIVE LANDSCAPE
16.1. Zoetis Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. Neogen Corporation
16.3. Antech Diagnostics, Inc.
16.4. IDEXX Laboratories, Inc.
16.5. Embark Veterinary, Inc.
16.6. Boehringer Ingelheim Animal Health USA Inc.
16.7. Arizona Veterinary Oncology
16.8. Varian Medical Systems, Inc.
16.9. Merck & Co., Inc.
16.10. Oncotect, Inc.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Animal Type (Canine, Feline, Others)
5.2.2. By Test Type (Blood Tests, Biopsy, Genome Testing, Endoscopy, Urinalysis, Imaging)
5.2.3. By Cancer Type (Lymphoma, Sarcomas, Mammary Gland Tumors, Skin Cancers, Others)
5.2.4. By End User (Reference Laboratories, Veterinary Hospitals and Clinics, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH-EAST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Animal Type
6.2.2. By Test Type
6.2.3. By Cancer Type
6.2.4. By End User
7. MID-WEST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Animal Type
7.2.2. By Test Type
7.2.3. By Cancer Type
7.2.4. By End User
8. WEST VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Animal Type
8.2.2. By Test Type
8.2.3. By Cancer Type
8.2.4. By End User
9. SOUTH VETERINARY ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Animal Type
9.2.2. By Test Type
9.2.3. By Cancer Type
9.2.4. By End User
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. POLICY & REGULATORY LANDSCAPE
13. UNITED STATES ECONOMIC PROFILE
14. UNITED STATES VETERINARY ONCOLOGY DIAGNOSTICS MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. COMPETITIVE LANDSCAPE
16.1. Zoetis Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. Neogen Corporation
16.3. Antech Diagnostics, Inc.
16.4. IDEXX Laboratories, Inc.
16.5. Embark Veterinary, Inc.
16.6. Boehringer Ingelheim Animal Health USA Inc.
16.7. Arizona Veterinary Oncology
16.8. Varian Medical Systems, Inc.
16.9. Merck & Co., Inc.
16.10. Oncotect, Inc.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
